Autoimmune Diseases
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Subtype terms (31)
More specific conditions that are subtypes of Autoimmune Diseases in the MeSH hierarchy.
- Addison Disease
10 drugs (8 approved, 2 experimental)
- Anemia, Hemolytic, Autoimmune
53 drugs (31 approved, 22 experimental)
- Anti-Glomerular Basement Membrane Disease
5 drugs (1 approved, 4 experimental)
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
48 drugs (29 approved, 19 experimental)
- Antiphospholipid Syndrome
35 drugs (24 approved, 11 experimental)
- Arthritis, Juvenile
95 drugs (71 approved, 24 experimental)
- Arthritis, Rheumatoid
638 drugs (246 approved, 392 experimental)
- Autoimmune Diseases of the Nervous System
26 drugs (16 approved, 10 experimental)
- Autoimmune Hypophysitis
- Autoimmune-Inflammatory Syndrome Induced by Adjuvants
- Autoimmune Inner Ear Disease
- Autoimmune Lymphoproliferative Syndrome
7 drugs (5 approved, 2 experimental)
- Autoimmune Pancreatitis
3 drugs approved
- Birdshot Chorioretinopathy
2 drugs approved
- Dermatitis Herpetiformis
9 drugs (7 approved, 2 experimental)
- Diabetes Mellitus, Type 1
438 drugs (212 approved, 226 experimental)
- Glomerulonephritis, IGA
81 drugs (46 approved, 35 experimental)
- Glomerulonephritis, Membranous
36 drugs (23 approved, 13 experimental)
- Graves Disease
37 drugs (24 approved, 13 experimental)
- Hepatitis, Autoimmune
30 drugs (18 approved, 12 experimental)
- Immunoglobulin G4-Related Disease
30 drugs (20 approved, 10 experimental)
- Latent Autoimmune Diabetes in Adults
5 drugs (4 approved, 1 experimental)
- Linear IgA Bullous Dermatosis
3 drugs (1 approved, 2 experimental)
- Lupus Erythematosus, Systemic
362 drugs (137 approved, 225 experimental)
- Ophthalmia, Sympathetic
3 drugs approved
- Pemphigoid, Bullous
30 drugs (22 approved, 8 experimental)
- Pemphigus
44 drugs (27 approved, 17 experimental)
- Polyendocrinopathies, Autoimmune
1 drug approved
- Purpura, Thrombocytopenic, Idiopathic
106 drugs (70 approved, 36 experimental)
- Thyroiditis, Autoimmune
9 drugs (6 approved, 3 experimental)
- Undifferentiated Connective Tissue Diseases
4 drugs approved
Drugs by status
Approved for this indication (10)
Phase 4 trials (17)
Phase 3 trials (23)
- vitamin d3
- nitroglycerin
- methylprednisolone
- abetimus
- golimumab
- tacrolimus
- naltrexone
- lymphocyte immune globulin, anti-thymocyte globulin (equine)
- hydroxychloroquine
- Filgrastim
- inebilizumab
- human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant
- mycophenolate
- cyclophosphamide
- abatacept
- tabalumab
- autologous mononuclear stem cell
- methotrexate
- sargramostim
- azathioprine
- efgartigimod
- imlifidase
- rhgad65
Phase 2 trials (64)
- melatonin
- azacitidine
- secukinumab
- Branebrutinib
- busulfan
- exenatide
- eculizumab
- efalizumab
- etanercept
- fab-fragment of anti-human cd4
- gsk2618960
- bone marrow derived mesenchymal stem cells
- aldesleukin
- ifetroban
- khk4083
- levamisole
- niacin
- ocrelizumab
- pentostatin
- adalimumab
- carmustine
- sparsentan
- allogeneic hematopoietic stem cells
- diamyd
- sirolimus
- cyclosporine
- tocilizumab
- alemtuzumab
- ublituximab
- Anti-thymocyte Globulin (Rabbit)
- +34 more
Phase 1 trials (74)
- cbp-307
- lipopolysaccharide
- gadoteric acid
- gsk2982772
- gsk3050002
- gsk706769
- rosuvastatin
- rifampin
- Sovleplenib
- hydrogen
- nivolumab
- belumosudil
- keyhole limpet hemocyanin
- montanide isa 720
- cep-37440
- Rilzabrutinib
- rilonacept
- sitagliptin
- Ivarmacitinib
- siplizumab
- tak-079
- rabeprazole
- itraconazole
- ashwagandha extract
- dapirolizumab pegol
- autologous mesenchymal stem cells
- sulfadoxine
- azithromycin
- ketoconazole
- pioglitazone
- +44 more
Other trials (25)
- clofarabine
- betamethasone
- l-glutamine
- fibrinogen (human)
- hydrocortisone
- potassium iodide
- Telitacicept
- ribavirin
- leflunomide
- hepatitis a vaccine, inactivated
- allogeneic cord blood
- bifidobacterium bifidum
- triamcinolone
- albuterol
- glatiramer acetate
- blood plasma
- prednisolone
- voriconazole
- fish oil
- Lactobacillus acidophilus
- lactobacillus casei
- iguratimod
- lactobacillus rhamnosus
- calculus bovis sativus
- str-p004
Organizations
Organization Involved with Phase 4 Indications (15)
- Gilead Sciences
- Merck Serono
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institute of Mental Health (NIMH)
- Peter J. Ruane, M.D.
- Harvard University
- University of Iowa
- Utrecht University
- Peking University
- State University of New York
- Zhejiang University
- University of Toulouse
- University of Sao Paulo
- Baird Multiple Sclerosis Center
- National Institute for Public Health and the Environment, RIVM, Holland
Organization Involved with Phase 3 Indications (26)
- Zenyaku Kogyo Co., Ltd.
- Merck
- Eli Lilly
- Novartis
- La Jolla Pharmaceutical Company
- MediQuest Therapeutics
- Savara Inc.
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of London
- Duke University
- University of Washington
- Johns Hopkins University
- Seoul National University
- University of Kentucky
- University of Adelaide
- University of California, Los Angeles
- University of Cincinnati
- Janssen Pharmaceutica NV
- University of Texas at Houston
- University of New South Wales
- Presbyterian/St. Luke's Medical Center, Denver
- Japan Agency for Medical Research and Development
- Johnson and Johnson
- Rouen Normandy University
- Ruhrlandklinik University Hospital, Essen, Germany
- Tokyo University
Organization Involved with Phase 2 Indications (44)
- Celgene
- Bristol-Myers Squibb
- Genentech
- Baxalta
- Biotectid GmbH
- Cumberland Pharmaceuticals
- Diamyd
- GlaxoSmithKline
- ImmusanT, Inc.
- Kyowa Hakko Kirin
- Stem Cells Arabia
- Fundación Pública Andaluza
- National Cancer Institute (NCI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Emory University
- Nanjing Medical University
- Nanjing University
- University of Leicester
- University of Miami
- University of Seville
- University of Leipzig
- Groupe Francophone des Myelodysplasies
- University of California, Davis
- University of California, San Francisco
- University of Cambridge
- Vanderbilt University
- Tsinghua University
- Zhongsh Ophthalmic Center
- University of Oxford
- Chu De Liège
- +14 more
Organization Involved with Phase 1 Indications (29)
- CSL Behring
- Kadmon
- Takeda
- MedImmune
- Biogen
- IASO Pharma Inc.
- Genexine, Inc.
- National Institutes of Health (NIH)
- National Eye Institute (NEI)
- Huazhong University of Science and Technology
- Celal Bayar University
- Ege University
- Hoosier Cancer Research Network
- National College of Natural Medicine
- Radboud University
- Russian Academy of Medical Sciences
- Icahn School of Medicine at Mount Sinai
- Alliance Foundation Trials
- Nucleus Network Ltd
- Quotient
- Suzhou Connect Biopharmaceuticals
- University of Erlangen-Nuremberg
- Immune Tolerance Network
- Tigermed Consulting Co., Ltd
- National Center for Advancing Translational Science (NCATS)
- The Scientific and Technological Research Council of Turkey
- Helfgott Research Institute
- IQVIA
- SinoMab Pty Ltd
Organization Involved with Other Experimental Indications (14)
- Laboratoire français de Fractionnement et de Biotechnologies
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Joslin Diabetes Center
- Stanley Medical Research Institute
- Tanta University
- Thomas Jefferson University
- Wake Forest University
- University of Lille
- McPin Foundation
- Latvian Biomedical Research and Study Centre
- Riga Stradins University
- Riga Maternity hospital
- Latvian Institute of Organic Synthesis
- Nemours Children's Health System